Tamgo T
A powerful dual-action combination of an alpha-1A blocker and a PDE5 inhibitor for comprehensive management of BPH/LUTS — improving urinary flow while addressing associated erectile dysfunction.
What is Tamgo T?
Tamgo T is a branded pharmaceutical combination product by Inspiron Scientific Pvt. Ltd. containing Tamsulosin Hydrochloride 0.4mg (Prolonged-Release) and Tadalafil 5mg in a single tablet. It represents a modern dual-action approach to managing Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), along with co-existing Erectile Dysfunction (ED).
Tamgo T addresses two common and often coexisting conditions in aging men. Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle to improve urine flow. Tadalafil inhibits phosphodiesterase-5 (PDE5) enzyme, increasing smooth muscle relaxation in the prostate, bladder, and penile vasculature — providing both urinary symptom relief and improvement in erectile function.
Detailed Product Information
Comprehensive information about Tamgo T — from composition and dual mechanism of action to dosage, clinical benefits, and storage guidelines.
Tamgo T Dual Action
Tamgo T combines Tamsulosin HCl 0.4mg (Prolonged-Release) with Tadalafil 5mg in a single convenient tablet. This dual-action formulation addresses both the obstructive and irritative urinary symptoms of BPH while simultaneously improving erectile function. The prolonged-release Tamsulosin ensures steady plasma levels throughout the day, while Tadalafil provides continuous smooth muscle relaxation via PDE5 inhibition.
Key Features — Tamgo T
- Dual-action formula: Alpha-1A blockade + PDE5 inhibition in one tablet
- Addresses both LUTS/BPH and erectile dysfunction simultaneously
- Prolonged-release Tamsulosin for consistent 24-hour urinary relief
- Clinically proven improvement in IPSS (International Prostate Symptom Score)
- Improved patient compliance with single-tablet regimen
- Well-tolerated with a favorable safety profile
- Convenient once-daily dosing after meals
• Tamsulosin Hydrochloride 0.4mg (Prolonged-Release)
• Tadalafil 5mg
Dosage Form: Prolonged-Release Film-Coated Tablets
Route: Oral Administration
Category: Alpha-1A Adrenergic Blocker + PDE5 Inhibitor
Marketed by: Inspiron Scientific Pvt. Ltd.
Tadalafil (PDE5 Inhibitor): Inhibits phosphodiesterase type 5 enzyme, increasing cyclic GMP levels. This leads to smooth muscle relaxation in the prostate, bladder, urethra, and penile corpus cavernosum — providing dual benefit for both urinary symptoms and erectile function.
- Lower Urinary Tract Symptoms (LUTS) associated with BPH
- Benign Prostatic Hyperplasia (BPH) with obstructive symptoms
- BPH with co-existing Erectile Dysfunction (ED)
- Urinary hesitancy, weak stream, and incomplete emptying
- Increased urinary frequency and urgency due to BPH
- Nocturia associated with prostatic enlargement
- Synergistic dual action — Alpha-1A blockade + PDE5 inhibition for comprehensive relief
- Superior IPSS improvement — Greater prostate symptom score reduction vs. monotherapy
- Improved urine flow — Significant increase in maximum urinary flow rate (Qmax)
- ED treatment — Restores erectile function in BPH patients with co-existing ED
- Single-tablet convenience — Improved compliance vs. taking two separate medications
- Well-tolerated — Favorable safety profile in clinical studies
Administration: Take approximately 30 minutes after the same meal each day (preferably after dinner). Swallow whole with water — do not crush, chew, or break the tablet (prolonged-release formulation).
Special Populations: Use with caution in patients with moderate hepatic impairment. Not recommended in severe hepatic or severe renal impairment. Contraindicated with nitrates and alpha-blockers other than Tamsulosin.
Duration: As directed by the prescribing physician. Clinical benefits are typically observed within 1–2 weeks for urinary symptoms.
Packaging: Available in alu-alu blister packs for optimal protection of the prolonged-release tablets.
Shelf Life: As mentioned on the pack. Do not use after the expiry date.
Special Note: Do not split, crush, or chew tablets. The prolonged-release coating is essential for proper Tamsulosin drug delivery and consistent plasma levels over 24 hours.
Understanding BPH & LUTS
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that commonly affects men as they age. The enlarged prostate compresses the urethra, leading to Lower Urinary Tract Symptoms (LUTS) that include difficulty starting urination, weak stream, frequent urination, and nocturia (nighttime urination).
BPH is not prostate cancer, but it can significantly impact quality of life. Many men also experience erectile dysfunction (ED) alongside BPH, as both conditions share common pathophysiological pathways involving smooth muscle tone and blood flow. Tamgo T uniquely addresses both concerns with its combination of Tamsulosin and Tadalafil, offering comprehensive relief through a single daily tablet.
Common Symptoms of BPH/LUTS
Recognizing these symptoms early can lead to timely treatment and significantly improved quality of life. Consult your doctor if you experience:
How Tamgo T Helps
Tamgo T works through two complementary pathways — Alpha-1A receptor blockade and PDE5 inhibition — to deliver comprehensive relief from both BPH/LUTS and erectile dysfunction.
- Take Tamgo T only as prescribed by your doctor — do not self-medicate
- Take approximately 30 minutes after the same meal each day; swallow tablet whole
- Do not crush, chew, or break the prolonged-release tablet
- Contraindicated with nitrates (e.g., nitroglycerin, isosorbide) — risk of severe hypotension
- Do not combine with other alpha-blockers or PDE5 inhibitors
- Monitor blood pressure, especially during initial treatment; risk of orthostatic hypotension
- May cause dizziness, headache, nasal congestion, or back pain as common side effects
- Report any prolonged erection (>4 hours) or sudden vision/hearing changes immediately
- If urinary symptoms worsen or do not improve after 2–4 weeks of treatment
- If you experience blood in urine, painful urination, or urinary retention
- If you develop dizziness, fainting, or signs of low blood pressure
- If you have a history of cardiovascular disease, stroke, or heart attack
- If you have severe liver or kidney disease
- If you experience a prolonged or painful erection lasting more than 4 hours (priapism)
- If you experience sudden decrease or loss of vision or hearing
- Before starting any new medications, especially nitrates or other alpha-blockers
Discover Inspiron Scientific's complete range of pharmaceutical products.
Ready to Partner
With Inspiron Scientific?
Whether you're a healthcare provider seeking quality pharmaceutical products, a distributor exploring partnership opportunities, or a professional looking to join our team — we'd love to hear from you.
Connect With Inspiron Scientific
Our team is available to discuss how Inspiron Scientific can support your healthcare needs. Reach out today.
AIMS, Ponekara (P.O.),
PIN – 682041, Kochi, Kerala
Door No. 37/558-P, Q, R, N,
Near Govt. Ayurveda Hospital,
Mullampara, Manjeri (P.O.) – 676121, Kerala
9:00 AM – 7:00 PM IST
Enquiry Form
Fill out the form below and our team will contact you promptly.
Our Quality Commitment
At Inspiron Scientific, quality is non-negotiable. Every product in our portfolio is sourced from WHO-GMP certified manufacturing partners and undergoes rigorous quality assurance processes. We stand behind the safety, efficacy, and consistency of every medicine we deliver.